Resolvyx Pharmaceuticals

... the end in inflammation

Publications

Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro.

T Lund, SM Mangsbo, H Scholz, P Gjorstrup, TH Tötterman, O Korsgren, A Foss.
Exp Clin Endocrinol Diabetes.
2010;118(4):237-44. Epub 2010


Neuroprotectin D1 attenuates laser-induced choriodal neovascularization in mouse.

KG Sheets, Y Zhou, MK Ertel, EJ Knott, CE Regan Jr, JR Elison, WC Gordon, P Gjorstrup, NG Bazan.
Molecular Vision.
2010; 16:320-29


Resolvin D2 is a potent regulator of leukocytes and control microbial sepsis

Matthew Spite, Lucy V. Norling, Lisa summers, Rong Yang, Dianne Cooper, Nicos A. Petasis, Roderick J. Flower, Mauro Perretti & Charles N. Serhan
Nature
October, 2009. Vol 46, pgs. 1287-1292.


Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis

Kip M Connor, John Paul SanGiovanni,Chatarina Lofqvist, Christopher M Aderman1, JingChen, Akiko Higuchi, Song Hong, Elke A Pravda1, Sharon Majchrzak, Deborah Carper, Ann Hellstrom, Jing X Kang, Emily Y Chew, Norman Salem Jr, Charles N Serhan & Lois E H Smith
Nature Medicine
July, 2007. Vol 13 No. 7, pgs. 868-873.


Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo

Hatice Hasturk, Alpdogan Kantarci, Emilie Goguet-Surmenian, Amanda Blackwood, Chris Andry, Charles N. Serhan, and Thomas E. VanDyke
The Journal of Immunology
2007, pgs. 7021-7029.


Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Charles N. Serhan, Nan Chiang and Thomas E. Van Dyke
Natures Reviews|Immunology
May, 2008. Vol 8 pgs. 349-361.


Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis

Makoto Arita, Masaru Yoshida, Song Hong, Eric Tjonahen, Jonathan N. Glickman, Nicos A. Petasis, Richard S. Blumberg, and Charles N. Serhan
Proceedings of the National Academy of Sciences
May 24, 2005. Vol 102 No. 21, pgs. 7671-7676.
http://www.pnas.org/cgi/content/abstract/102/21/7671


Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

Charles N. Serhan, Song Hong, Karsten Gronert, Sean P. Colgan, Pallavi R. Devchand, Gudrun Mirick, and Rose-Laure Moussignac
Journal of Experimental Medicine
October 2002; Vol 196 No 8, pgs 1025-1037.
http://www.jem.org/cgi/content/full/196/8/1025


Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions

Makoto Arita, Sungwhan F. Oh, Tomomichi Chonan, Song Hong, Siva Elangovan, Yee-Ping Sun, Jasim Uddin, Nicos A. Petasis, and Charles N. Serhan
Journal of Biological Chemistry
Aug 2006; 281: 22847 - 22854 ; doi:10.1074/jbc.M603766200
http://www.jbc.org/cgi/content/abstract/281/32/22847


Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.

Makoto Arita, Francesca Bianchini, Julio Aliberti, Alan Sher, Nan Chiang, Song Hong, Rong Yang, Nicos A. Petasis, and Charles N. Serhan
Journal of Experimental Medicine
Vol. 201 No. 5, March 7, 2005, pgs. 713-722
http://www.jem.org/cgi/doi/10.1084/jem.20042031


Novel docasatrienes and 17S-Resolvins generated from docasahexaenoic acid in murine brain, human blood glial cells

Song Hong, Karsten Gronert, Pallavi R. Devchand, Rose-Laure Moussignac, and Charles N. Serhan
Journal of Biological Chemistry
Vol. 278, No. 17, April 25, 2003, pgs 14677-14687
http://www.jbc.org/cgi/content/full/278/17/14677


RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis

H. Hasturk, A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. Petasis, B.D. Levy, C.N. Serhan and T.E. Van Dyke
Federation of American Societies for Experimental Biology
published online December 29, 2005
http://www.fasebj.org/cgi/content/abstract/05-4724fjev1

Resolvins modify function of several pathways in a "many-to-one" approach with a high potential for efficacy across different etiologies and pathologies